Abstract 2424
Background
Prognosis of metastatic pancreatic adenocarcinoma is gloomy. To elicit a chemotherapy regimen with higher efficiency and with lower toxicities is critical important.
Methods
This was a one arm, phase 2, three-center study. Enrolled patients were histological or pathologically confirmed; treatment naïve metastatic pancreatic adenocarcinoma. Enrolled patients were 18 years or older, with at least one measurable lesion and performance status between 0-2 with ECOG score. Irrinotecan 165 mg/m2 and oxaliplatin 85 mg/m2 were administered intravenous infusion on days 1, and S1 40 mg/m2 was administered orally on day 1-14, every 21 day a cycle until progressive disease or intolerable toxicities or patient death. The primary endpoint was overall survival and the second endpoints were progression-free survival and toxicities.
Results
A total of 41 patients were enrolled, median age was 59 year-old. There were 18 men and 23 women. The median progression-free survival was 4.33 (95% CI: 2.83-5.88) and median overall survival was 11.00 (95% CI: 9.16-12.84). There were 38 patients validated for efficiency evaluation. There was no complete response, the partial response rate, stable disease and progression disease was 42.11% (16/38), 31.58% (12/38) and 26.32% (10/38) respectively. The most common adverse effect was mild to moderate nausea, vomiting, neutropenia and thrombocytopenia. The 3/4 degree neutropenia and thrombocytopenia were 29.27% (12/41) and 12.20% (5/41) respectively.
Conclusions
Irinotecan combined with oxaliplatin and S1 was effective in metastatic pancreatic adenocarcinoma; its toxicities were mild to moderate and tolerable. Furthermore, patients to enrol the study is needed.
Clinical trial identification
NCT03726021.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4778 - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis
Presenter: Yi-wen Zhang
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract
3248 - Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: a population-based study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract